Literature DB >> 8648060

Genotypes of hepatitis C virus in Taiwan and the progression of liver disease.

J H Kao1, P J Chen, M Y Lai, P M Yang, J C Sheu, T H Wang, D S Chen.   

Abstract

The existence of four genotypes of hepatitis C virus (HCV)--types 1a, 1b, 2a, and 2b--has been suggested based on variations in nucleotide sequences of the core region. The aim of this study was to investigate the prevalence of HCV genotypes in chronic type C liver disease in Taiwan and correlate distinct genotypes to severity of liver disease. The genotypes of 175 patients with chronic type C liver disease were determined by a polymerase chain reaction with type-specific primers. The prevalence of each genotype in Taiwan was as follows: type 1a, n = 1 (0.6%); 1b, n = 125 (71.4%); 2a, n = 21 (12%); 2b, n = 6 (3.4%); mixed types, n = 18 (10.3%); and unclassified, n = 4 (2.3%). The demographic and clinical features were comparable between patients with different genotypes, except that the mean peak serum transaminase levels of patients with double viruses and type 1b HCV infections were significantly higher than were those of patients with type 2a virus. Moreover, type 1b HCV was more prevalent in patients with liver cirrhosis alone or with hepatocellular carcinoma. In conclusion, type 1b virus is the predominant genotype in chronic hepatitis C in Taiwan, and type 1b virus and mixed infection may trigger more severe liver disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8648060     DOI: 10.1097/00004836-199510000-00014

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  7 in total

Review 1.  Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.

Authors:  Maria Victoria Preciado; Pamela Valva; Alejandro Escobar-Gutierrez; Paula Rahal; Karina Ruiz-Tovar; Lilian Yamasaki; Carlos Vazquez-Chacon; Armando Martinez-Guarneros; Juan Carlos Carpio-Pedroza; Salvador Fonseca-Coronado; Mayra Cruz-Rivera
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

2.  The accuracy of sonography in predicting steatosis and fibrosis in chronic hepatitis C.

Authors:  Chien-Hua Chen; Shang-Tao Lin; Chi-Chieh Yang; Yung-Hsiang Yeh; Chien-Long Kuo; Chiu-Kue Nien
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

Review 3.  Advanced molecular surveillance of hepatitis C virus.

Authors:  Livia Maria Gonçalves Rossi; Alejandro Escobar-Gutierrez; Paula Rahal
Journal:  Viruses       Date:  2015-03-13       Impact factor: 5.048

4.  Sexually-transmitted hepatitis C virus reinfections among people living with HIV in Taiwan: the emerging role of genotype 6.

Authors:  Guan-Jhou Chen; Hsin-Yun Sun; Sui-Yuan Chang; Li-Hsin Su; Yi-Ting Chen; Szu-Min Hsieh; Wan-Da Liu; Wang-Huei Sheng; Yu-Shan Huang; Kuan-Yin Lin; Yi-Ching Su; Wen-Chun Liu; Chien-Ching Hung
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

5.  Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients.

Authors:  Chuan-Mo Lee; Tsung-Hui Hu; Sheng-Nan Lu; Jing-Houng Wang; Chao-Hung Hung; Chien-Hung Chen; Yi-Hao Yen
Journal:  BMC Gastroenterol       Date:  2016-07-25       Impact factor: 3.067

6.  Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells.

Authors:  Yu-Yun Shao; Min-Shu Hsieh; Han-Yu Wang; Yong-Shi Li; Hang Lin; Hung-Wei Hsu; Chung-Yi Huang; Chih-Hung Hsu; Ann-Lii Cheng
Journal:  Oncotarget       Date:  2017-09-30

7.  Hepatitis C Virus Subtypes Novel 6g-Related Subtype and 6w Could Be Indigenous in Southern Taiwan with Characteristic Geographic Distribution.

Authors:  Hung-Da Tung; Pei-Lun Lee; Jyh-Jou Chen; Hsing-Tao Kuo; Ming-Jen Sheu; Chun-Ta Cheng; Tang-Wei Chuang; Hsu-Ju Kao; Yu-Hsun Wu; Mai-Gio Pang; Cheng-Heng Lin; Chia-Yi Hou; Hsin-Hua Tsai; Li-Ching Wu; Chuan Lee
Journal:  Viruses       Date:  2021-07-07       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.